|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
How A Cancer Vaccine and Keytruda Work to Treat Patients With Melanoma
2
Pancreatic Cancer Treatment Options and Strategies for Patients
3
How Ikebana Helped Me Navigate Life With Cancer
4
Cancer Vaccine Plus Keytruda Reduces Melanoma Recurrence or Death
5